A US retrospective cohort study found no association between angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) use and COVID-19 test positivity. The study included 18 472 patients tested for COVID-19 (mean age 49 years, 40% male, and 69% white), 12.4% were taking either ACEIs or ARBs. A positive COVID-19 test result was observed in 9.4% of patients. Among patients who tested positive, 24.3% were admitted to the hospital, 9.3% were admitted to an intensive care unit, and 6.4% required mechanical ventilation. Overlap propensity score weighting showed no significant association of ACEI and/or ARB use with COVID-19 test positivity. These data support various society guidelines to continue current treatment of chronic disease conditions with either ACEI or ARB during the COVID-19 pandemic. Source: https://jamanetwork.com/
A US prospective study found that moderate egg consumption was associated with a significantly lower…
Anxiety disorders are common yet often underrecognized in primary care, but a review shows that…
Two-dose recombinant zoster vaccination (RZV) was associated with a significantly lower risk of new-onset dementia,…
A 13-year follow-up of a randomized controlled trial found that a single colonoscopy screening significantly…
Higher consumption of ultra-processed foods (UPFs) is associated with poorer attention and increased modifiable dementia…
Blood pressure (BP)-lowering treatment significantly reduces the risk of major cardiovascular events in individuals with…
This website uses cookies.